Jump to content
Powered by

Cytonet cooperates with Hamad Medical Corporation in Doha, Qatar

Joint Venture between Weinheim Biotech-Company Cytonet, the University Children’s Hospital in Heidelberg and the Hamad Medical Corporation (HMC) in Doha, Qatar to promote Liver Cell Therapy.

(left to right) Michael J. Deissner (Managing Director of Cytonet, Weinheim), Prof. Dr. Georg F. Hoffmann (Head of the University Children’s Hospital, Heidelberg), Dr. Hanan Al Kuwari (Managing Director of Hamad Medical Corporation, Doha), Dr. Wolfgang Rüdinger (Managing Director of Cytonet), Dr. Hilal Al Rifai (Chief of Medical Staff, Paediatrics Department, HMC, Doha) © Cytonet

The German biotech company Cytonet GmbH & Co. KG in Weinheim, the University Children's Hospital in Heidelberg and the Hamad Medical Corporation (HMC) medical centre in Doha, Qatar have signed a partnership agreement: a joint venture between the Weinheim specialist for regenerative medicine and the two renowned clinics was sealed on 11 October 2010 during the Newborn-Screening-Congress in Doha, Qatar. This close cooperation should enable affected children who suffer from urea cycle defects to be quickly included in the German liver cell therapy study programme that is being developed by Cytonet. This future treatment option for urea cycle defects - severe and life-threatening metabolic disorders of the liver - is currently undergoing clinical examination. Within the framework of this cooperation agreement, physicians are also to be given further training as they work together with the metabolic experts at Heidelberg University Hospital. Leading investigator is Prof. Dr. Georg Hoffmann, Head of the University Children's Hospital in Heidelberg, who is a long-standing cooperation partner of Cytonet.

Dr. Ghassan Mustafa Abdoh, Head of the Newborn Screening Unit, Paediatrics Department, Hamad Medical Corporation, Doha / Qatar commented: "We at HMC are delighted to be participating in the further development of this very important option of treating those who are affected and we are very glad that we can now offer our most seriously ill patients the possibility of being quickly included in the SELICA V study. Because, apart from a liver transplantation, which is often not possible - especially in affected newborns - there are no alternative curative treatment options for urea cycle defects." Dr. Wolfgang Rüdinger and Michael J. Deissner, the managing directors of Cytonet, were also in agreement "that this international cooperation represents another forward step on the road to making liver cell therapy available and usable at all times in every metabolic center".

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/cytonet-cooperates-with-hamad-medical-corporation-in-doha-qatar